Hemp - the Austrian medicinal plant 2018

The Herbal Medicinal Products Platform Austria, a scientific network of experts from the pharmaceutical institutes of the Universities of Vienna, Graz, and Innsbruck, annually selects a medicinal plant of the year. This year, the award went to the hemp plant (Cannabis sativa). Reasons given for the selection include its current importance, the diversity of interesting pharmacologically active ingredients, and the fact that hemp is now cultivated in Austria for medicinal purposes.
Philip Schmiedhofer, MSc

Autor

Philip Schmiedhofer, MSc

Inhaltsverzeichnis

Our commentary on: Hemp - the Austrian medicinal plant 2018

We are convinced that the hemp plant should not be held solely in the hands of the medicine trade

Our comment on: Hemp - the Austrian medicinal plant 2018

We are convinced that the hemp plant should not be held exclusively by the pharmaceutical industry – after all, it is one of the oldest cultivated plants in the world – and therefore should be available to all people at all times, even beyond medical uses. The medical applications of ingredients from the cannabis plant are diverse – especially of CBD and THC.

Philip Schmiedhofer, MSc

Philip Schmiedhofer, MSc

Philip is managing director and co-founder of cannhelp GmbH. With studies in medical engineering and molecular biology, specializing in brain sciences and focusing on cannabinoids, he is recognized as an expert in the use of cannabinoids in medicine. As a medical device consultant, he also leads the sales of cannmedic and offers specialized advice for medical professionals. His expertise includes the development and sales of cannabinoid-based products. In research, he participates in significant basic research at the Centre for Brain Research at the Medical University of Vienna. As co-founder and current managing director of cannmedic GmbH, a pioneer in the trade of CBD medical products, he has many years of entrepreneurial experience. Furthermore, he maintains an extensive network in the field and advises internationally operating companies in the area of medical cannabinoids.